← Leaderboards
Janis M. Taube
Johns Hopkins University
$2,419,751
Attributed
$6,279,764
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $812.5K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,279,764 · 2
By mechanism
R01$5,863,502 · 1
UH2$416,262 · 1
Top collaborators
- Drew M. Pardoll11 shared
- Suzanne Louise Topalian10 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Drew M. Pardoll$27,059,898
- Se-Jin Lee$17,681,857
- Douglas James Digirolamo$2,003,410
- Kellie Nicole Smith$2,071,828
- Joseph L Mankowski$32,075,460
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaCell TypeBiological MarkersCombinatorialTumorImmuneNeoplastic CellTissuesSpecimenSolid NeoplasmTumor MicroenvironmentCellsResponseResistanceMembraneAnti-Pd-L1Anti-Pd1 TherapyPd-1 PathwayPd-1/Pd-L1ImmunotherapyIn Vivo ModelAnti-Pd-1FundingIn Vivo
Grant awards (13)
PD-1/PD-L1 modulation in cancer therapy$600,140
R01 · FY2025 · CA
PD-1/PD-L1 modulation in cancer therapy$570,133
R01 · FY2024 · CA
PD-1/PD-L1 modulation in cancer therapy$600,140
R01 · FY2023 · CA
Analytic and Clinical Validation of a 7-plex MIF Assay for Predictive Response of Advanced NSCLC to Anti-PD-1 based Therapy$191,915
UH2 · FY2023 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$588,135
R01 · FY2022 · CA
Analytic and Clinical Validation of a 7-plex MIF Assay for Predictive Response of Advanced NSCLC to Anti-PD-1 based Therapy$224,347
UH2 · FY2022 · CA · contact PI
PD-1/PD-L1 modulation in cancer therapy$600,139
R01 · FY2021 · CA
PD-1/PD-L1 modulation in cancer therapy$672,206
R01 · FY2020 · CA
PD-1/PD-L1 modulation in cancer therapy$473,681
R01 · FY2019 · CA
Multi-institutional analysis of multiplex immunofluorescence panels in tumor tissue specimens$293,932
R01 · FY2019 · CA
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2018 · CA
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2017 · CA
PD-1/PD-L1 modulation in cancer therapy$488,332
R01 · FY2016 · CA